Kobayashi will maintain its edge in Japan and develop more “hidden ponds†overseas.
Narrow-moat Kobayashi Pharmaceutical announced the acquisition of Jiangsu Zhongdan Pharmaceutical, a drug manufacturer in Jiangsu, China, aiming to accelerate the expansion of its over-the-counter drug business in the country. The acquisition is expected to be completed by June 30. While the price was not disclosed, we believe the deal itself will have only a marginal impact on Kobayashi’s earnings and return on investment, given that the revenue of the targeted firm is less than 1% of Kobayashi...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.